{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T03:35:12Z","timestamp":1761708912476},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1016\/j.ejphar.2013.12.013","type":"journal-article","created":{"date-parts":[[2013,12,17]],"date-time":"2013-12-17T18:45:20Z","timestamp":1387305920000},"page":"67-76","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Pranlukast inhibits renal epithelial cyst progression via activation of AMP-activated protein kinase"],"prefix":"10.1016","volume":"724","author":[{"given":"Nutthapoom","family":"Pathomthongtaweechai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunhapas","family":"Soodvilai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Varanuj","family":"Chatsudthipong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chatchai","family":"Muanprasat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2013.12.013_bib1","doi-asserted-by":"crossref","first-page":"52S","DOI":"10.1378\/chest.111.2_Supplement.52S","article-title":"Worldwide clinical experience with the first marketed leukotriene receptor antagonist","volume":"111","author":"Barnes","year":"1997","journal-title":"Chest"},{"key":"10.1016\/j.ejphar.2013.12.013_bib2","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/j.bbrc.2004.09.177","article-title":"AMPK inhibits fatty acid-induced increases in NF-kappaB transactivation in cultured human umbilical vein endothelial cells","volume":"324","author":"Cacicedo","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejphar.2013.12.013_bib3","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1124\/jpet.111.183020","article-title":"Nonsteroidal anti-inflammatory drug flufenamic acid is a potent activator of AMP-activated protein kinase","volume":"339","author":"Chi","year":"2011","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2013.12.013_bib4","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.abb.2010.05.003","article-title":"Regulation of SIRT1 in cellular functions: role of polyphenols","volume":"501","author":"Chung","year":"2010","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.ejphar.2013.12.013_bib5","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1159\/000083325","article-title":"Pranlukast, a leukotriene receptor antagonist, inhibits interleukin-5 production via a mechanism distinct from leukotriene receptor antagonism","volume":"136","author":"Fukushima","year":"2005","journal-title":"Int. Arch. Allergy Appl. Immunol."},{"key":"10.1016\/j.ejphar.2013.12.013_bib6","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1002\/jcb.23053","article-title":"Regulation of AMP-activated protein kinase by LKB1 and CaMKK in adipocytes","volume":"112","author":"Gormand","year":"2011","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.ejphar.2013.12.013_bib7","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1172\/JCI9622","article-title":"Inhibition of cystic fibrosis transmembrane conductance regulator by novel interaction with the metabolic sensor AMP-activated protein kinase","volume":"105","author":"Hallows","year":"2000","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ejphar.2013.12.013_bib8","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/nrm3311","article-title":"AMPK: a nutrient and energy sensor that maintains energy homeostasis","volume":"13","author":"Hardie","year":"2012","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ejphar.2013.12.013_bib9","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1046\/j.1365-2222.2003.01673.x","article-title":"Pranlukast inhibits NF-kappa B activation in human monocytes\/macrophages and T cells","volume":"33","author":"Ichiyama","year":"2003","journal-title":"Clin. Exp. Allergy (Journal of the British Society for Allergy and Clinical Immunology)"},{"key":"10.1016\/j.ejphar.2013.12.013_bib10","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1097\/01.ASN.0000028643.17901.42","article-title":"Genetics and pathogenesis of polycystic kidney disease","volume":"13","author":"Igarashi","year":"2002","journal-title":"J. Am. Soc. Nephrol.: JASN"},{"key":"10.1016\/j.ejphar.2013.12.013_bib11","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1159\/000081294","article-title":"Pranlukast inhibits NF-kappaB activation and MUC2 gene expression in cultured human epithelial cells","volume":"73","author":"Ishinaga","year":"2005","journal-title":"Pharmacology"},{"key":"10.1016\/j.ejphar.2013.12.013_bib12","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.bcp.2013.05.005","article-title":"Cysteinyl leukotriene-receptor-1 antagonists interfere with PGE2 synthesis by inhibiting mPGES-1 activity","volume":"86","author":"Kahnt","year":"2013","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejphar.2013.12.013_bib13","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1089\/ars.2006.1456","article-title":"Effects of PGC-1alpha on TNF-alpha-induced MCP-1 and VCAM-1 expression and NF-kappaB activation in human aortic smooth muscle and endothelial cells","volume":"9","author":"Kim","year":"2007","journal-title":"Antioxidants Redox Signal."},{"key":"10.1016\/j.ejphar.2013.12.013_bib14","doi-asserted-by":"crossref","first-page":"e22363","DOI":"10.1371\/journal.pone.0022363","article-title":"Differential inhibitory effects of CysLT(1) receptor antagonists on P2Y(6) receptor-mediated signaling and ion transport in human bronchial epithelia","volume":"6","author":"Lau","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2013.12.013_bib15","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1111\/j.1523-1755.2004.00967.x","article-title":"The relationship between cell proliferation, Cl-secretion, and renal cyst growth: a study using CFTR inhibitors","volume":"66","author":"Li","year":"2004","journal-title":"Kidney Int."},{"key":"10.1016\/j.ejphar.2013.12.013_bib16","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1038\/nm1783","article-title":"A tumor necrosis factor-alpha-mediated pathway promoting autosomal dominant polycystic kidney disease","volume":"14","author":"Li","year":"2008","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejphar.2013.12.013_bib17","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/sj.bjp.0701886","article-title":"Effects of the cysteinyl leukotriene receptor antagonists pranlukast and zafirlukast on tracheal mucus secretion in ovalbumin-sensitized guinea-pigs in vitro","volume":"124","author":"Liu","year":"1998","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2013.12.013_bib18","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s10157-012-0741-0","article-title":"Autosomal dominant polycystic kidney disease: recent advances in pathogenesis and potential therapies","volume":"17","author":"Mochizuki","year":"2013","journal-title":"Clin. Exp. Nephrol."},{"key":"10.1016\/j.ejphar.2013.12.013_bib19","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1254\/jphs.11153FP","article-title":"Novel action of the chalcone isoliquiritigenin as a cystic fibrosis transmembrane conductance regulator (CFTR) inhibitor: potential therapy for cholera and polycystic kidney disease","volume":"118","author":"Muanprasat","year":"2012","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.ejphar.2013.12.013_bib20","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1681\/ASN.2004090800","article-title":"Extracellular signal-regulated kinase inhibition slows disease progression in mice with polycystic kidney disease","volume":"17","author":"Omori","year":"2006","journal-title":"J. Am. Soc. Nephrol.: JASN"},{"key":"10.1016\/j.ejphar.2013.12.013_bib21","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.cell.2012.01.017","article-title":"Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases","volume":"148","author":"Park","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.ejphar.2013.12.013_bib22","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/nm.3092","article-title":"Defective glucose metabolism in polycystic kidney disease identifies a new therapeutic strategy","volume":"19","author":"Rowe","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejphar.2013.12.013_bib23","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1124\/mol.56.3.657","article-title":"Identification, molecular cloning, expression, and characterization of a cysteinyl leukotriene receptor","volume":"56","author":"Sarau","year":"1999","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejphar.2013.12.013_bib24","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/j.1748-1716.2011.02253.x","article-title":"Anion secretion by a model epithelium: more lessons from Calu-3","volume":"202","author":"Shan","year":"2011","journal-title":"Acta Physiol. (Oxford)"},{"key":"10.1016\/j.ejphar.2013.12.013_bib25","doi-asserted-by":"crossref","first-page":"5466","DOI":"10.1073\/pnas.0509694103","article-title":"The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease","volume":"103","author":"Shillingford","year":"2006","journal-title":"Proc. Nat. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejphar.2013.12.013_bib26","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1681\/ASN.2009040421","article-title":"Rapamycin ameliorates PKD resulting from conditional inactivation of Pkd1","volume":"21","author":"Shillingford","year":"2010","journal-title":"J. Am. Soc. Nephrol.: JASN"},{"key":"10.1016\/j.ejphar.2013.12.013_bib27","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1073\/pnas.1011498108","article-title":"Activating AMP-activated protein kinase (AMPK) slows renal cystogenesis","volume":"108","author":"Takiar","year":"2011","journal-title":"Proc. Nat. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejphar.2013.12.013_bib28","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1016\/j.bbadis.2011.01.011","article-title":"Fluid transport and cystogenesis in autosomal dominant polycystic kidney disease","volume":"1812","author":"Terryn","year":"2011","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ejphar.2013.12.013_bib29","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1046\/j.1365-2222.1999.00710.x","article-title":"Effects of ONO-1078 (pranlukast) on cytokine production in peripheral blood mononuclear cells of patients with bronchial asthma","volume":"29","author":"Tohda","year":"1999","journal-title":"Clin. Exp. Allergy (Journal of the British Society for Allergy and Clinical Immunology)"},{"key":"10.1016\/j.ejphar.2013.12.013_bib30","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/ki.2009.128","article-title":"Autosomal dominant polycystic kidney disease: the last 3 years","volume":"76","author":"Torres","year":"2009","journal-title":"Kidney Int."},{"key":"10.1016\/j.ejphar.2013.12.013_bib31","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/j.bbadis.2010.11.005","article-title":"Cyclic AMP-mediated cyst expansion","volume":"1812","author":"Wallace","year":"2011","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ejphar.2013.12.013_bib32","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1081\/JAS-100000021","article-title":"Effects of pranlukast, a leukotriene receptor antagonist, on airway inflammation in mild asthmatics","volume":"38","author":"Yamauchi","year":"2001","journal-title":"J. Asthma (Official Journal of the Association for the Care of Asthma)"},{"key":"10.1016\/j.ejphar.2013.12.013_bib33","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1681\/ASN.2007070828","article-title":"Small-molecule CFTR inhibitors slow cyst growth in polycystic kidney disease","volume":"19","author":"Yang","year":"2008","journal-title":"J. Am. Soc. Nephrol."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299913009400?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299913009400?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T16:03:46Z","timestamp":1726848226000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299913009400"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":33,"alternative-id":["S0014299913009400"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2013.12.013","relation":{},"ISSN":["0014-2999"],"issn-type":[{"type":"print","value":"0014-2999"}],"subject":[],"published":{"date-parts":[[2014,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pranlukast inhibits renal epithelial cyst progression via activation of AMP-activated protein kinase","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2013.12.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}